Pfizer and BioNTech shares rise on report FDA could fully approve COVID-19 vaccine next week

Pfizer Inc. and U.S.-listed shares of BioNTech SE rose in the extended session Friday following a report that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week. Pfizer shares rose more than 2% after hours, following a 0.2% decline to close at $48.72, and German-based BioNTech's ADRs rallied more than 5%, following a 5.1% gain to close at $348.68. Late Friday, The New York Times reported that the FDA could approve the vaccine, which up until now has been distributed on an emergency basis, as early as Monday but could possibly go past that if regulators need more time to review data. The Department of Health and Human Services recently announced thata third dose, or a booster, of the vaccine would be available in mid-September to those who already received their first two shots. Back in July, Pfizer and BioNTech reported encouraging data on a vaccine booster shot targeting the delta variant of the virus. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Pfizer and BioNTech shares rise on report FDA could fully approve COVID-19 vaccine next week
Pfizer Inc. and U.S.-listed shares of BioNTech SE rose in the extended session Friday following a report that the drug makers will likely get full Food and Drug Administration approval for their COVID-19 vaccine sometime next week. Pfizer shares rose more than 2% after hours, following a 0.2% decline to close at $48.72, and German-based BioNTech's ADRs rallied more than 5%, following a 5.1% gain to close at $348.68. Late Friday, The New York Times reported that the FDA could approve the vaccine, which up until now has been distributed on an emergency basis, as early as Monday but could possibly go past that if regulators need more time to review data. The Department of Health and Human Services recently announced thata third dose, or a booster, of the vaccine would be available in mid-September to those who already received their first two shots. Back in July, Pfizer and BioNTech reported encouraging data on a vaccine booster shot targeting the delta variant of the virus. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.